News
Final Takeaways: Screening, Cardiovascular Risk, and Treating Cortisol as the Root Cause
1+ hour, 38+ min ago (330+ words) Final Takeaways: Screening, Cardiovascular Risk, and Treating Cortisol as the Root Cause'HCPLive In the concluding segment, Ralph DeFronzo, MD, returns to a central message: hypercortisolism in difficult-to-control type 2 diabetes is substantially more common than many clinicians appreciate. He compares the…...
Screening in Primary Care: When and How to Use the Overnight Dexamethasone Suppression Test
3+ hour, 36+ min ago (352+ words) Screening in Primary Care: When and How to Use the Overnight Dexamethasone Suppression Test'HCPLive In this segment, Richard Auchus, MD, and Ralph DeFronzo, MD, examine why hypercortisolism remains underdiagnosed in the settings where most patients receive care'busy primary care and…...
Beyond Mifepristone: Enzyme Inhibitors, Pituitary-targeted Agents, and Emerging Therapies
7+ hour, 25+ min ago (363+ words) Beyond Mifepristone: Enzyme Inhibitors, Pituitary-targeted Agents, and Emerging Therapies'HCPLive In this segment, Richard Auchus, MD, broadens the discussion beyond mifepristone to review other medical therapies targeting cortisol synthesis and pituitary drivers of Cushing syndrome. He begins with metyrapone, a relatively…...
Practical Use of Mifepristone and the Need for Endocrinology–Primary Care Collaboration
7+ hour, 25+ min ago (318+ words) Practical Use of Mifepristone and the Need for Endocrinology'Primary Care Collaboration'HCPLive In this segment, Ralph DeFronzo, MD, elaborates on the practical magnitude of benefit observed with mifepristone in hypercortisolism, particularly in patients enrolled in trials like CATALYST. He reiterates that…...
Adherence, Specialty Pharmacies, and the Future of Precision Pediatric Care
9+ hour, 40+ min ago (245+ words) Adherence, Specialty Pharmacies, and the Future of Precision Pediatric Care'HCPLive Even the most advanced treatment plan is ineffective without adherence. In the final video in this series on management of atopic dermatitis and psoriasis in pediatric patients, Adelaide Hebert, MD,…...
HCPLive 5 Stories in Under 5: Week of 02/01
12+ hour, 13+ min ago (223+ words) An audio recap of the top 5 stories in healthcare news from the week of 02/01-02/07. 1. FDA Issues CRL to Dibutepinephrine (Anaphylm) Sublingual Film for Type 1 Allergic Reactions The FDA issued a Complete Response Letter for sublingual dibutepinephrine after identifying human factors…...
Residual Symptoms Do Not Predict MDD Relapse
20+ hour, 21+ min ago (52+ words) Residual Symptoms Do Not Predict MDD Relapse'HCPLive KDIGO 2025 Guides Mechanism-Driven Therapy in IgA Nephropathy, With Luis Russo, MD, MS Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis Contact Dermatitis Updates for 2026, With Walter Liszewski, MD Potential of…...
Spotlighting Updates in Psoriasis, PsA Management in 2026, With Philip Mease, MD
1+ day, 2+ hour ago (305+ words) This Q&A interview with Philip Mease, MD, highlights his contribution to the "Psoriasis Update 2026" talk given at the 2026 Maui Derm Hawaii meeting. A wide array of recent and upcoming updates in the psoriasis management space have been described in…...
Omissions and Oversights in the Dietary Guidelines: Where Does Fiber Fall?
1+ day, 10+ hour ago (59+ words) Omissions and Oversights in the Dietary Guidelines: Where Does Fiber Fall?HCPLive Most Marginalized Children with Uncontrolled Asthma Miss Specialist Care KDIGO 2025 Guides Mechanism-Driven Therapy in IgA Nephropathy, With Luis Russo, MD, MS Potential of Epinephrine Sublingual Film for Anaphylaxis,…...
Yuvezzi: The Future of Presbyopia Treatment
1+ day, 10+ hour ago (53+ words) Yuvezzi: The Future of Presbyopia Treatment'HCPLive Most Marginalized Children with Uncontrolled Asthma Miss Specialist Care KDIGO 2025 Guides Mechanism-Driven Therapy in IgA Nephropathy, With Luis Russo, MD, MS Potential of Epinephrine Sublingual Film for Anaphylaxis, With David Golden, MD Abelacimab Reduces…...